evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,359 questions · 2,491 findings · 249 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 696 · 27.9%GRADE not reported 213 · 8.6%Very low 611 · 24.5%Low 595 · 23.9%Moderate 315 · 12.6%High 61 · 2.4%

Three infusions of natalizumab (300 mg) vs placebo

Failure to induce clinical response at end of study · Patients with active Crohn's disease

Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce clinical response at 10 weeks compared with placebo (high certainty).

2 findings from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 2 weeks compared with placebo (moderate certainty).

2 findings from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo

Failure to induce remission at 6 weeks · Patients with active Crohn's disease

Two infusions of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 6 weeks compared with placebo (high certainty).

2 findings from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Minor bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review